Page 92 - Read Online

Schwarzenbach et al. Cancer Drug Resist 2019;2:271-96 I http://dx.doi.org/10.20517/cdr.2019.010 Page 291

REFERENCES
1. Noble D. Conrad Waddington and the origin of epigenetics. J Exp Biol 2015;218:816-8.
2. Waddington CH. The Epigenotype Endeavour 1942;1:18-20.
3. Waddington CH. The genetic basis of the 'assimilated bithorax' stock. J Genet 2006;85:101-5.
4. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59.
5. Yang Q, Yang Y, Zhou N, Tang K, Lau WB, et al. Epigenetics in ovarian cancer: premise, properties, and perspectives. Mol Cancer
2018;17:109.
6. Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode.
Nature 1965;205:698-9.
7. Rosenberg B, VanCamp L. The successful regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Res
1970;30:1799-802.
8. Wilting RH, Dannenberg JH. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist
Updat 2012;15:21-38.
9. Dawson MA, Kouzarides T, Huntly BJ. Targeting epigenetic readers in cancer. N Engl J Med 2012;367:647-57.
10. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, et al. Molecular biology of the cell. 5th ed. New York: Garland Science Publishing,
Taylor & Francis Group; 2008.
11. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer
2006;6:107-16.
12. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic
breast and ovarian tumors. J Natl Cancer Inst 2000;92:564-9.
13. Catteau A, Harris WH, Xu CF, Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation
with disease characteristics. Oncogene 1999;18:1957-65.
14. Gozzi G, Chelbi ST, Manni P, Alberti L, Fonda S, et al. Promoter methylation and downregulated expression of the TBX15 gene in
ovarian carcinoma. Oncol Lett 2016;12:2811-9.
15. Li Q, Xue X, Li W, Wang Q, Han L, et al. Heterogeneous DNA methylation status in same-cell subpopulations of ovarian cancer tissues.
Tumour Biol 2017;39:1010428317701650.
16. Losi L, Fonda S, Saponaro S, Chelbi ST, Lancellotti C, et al. Distinct DNA methylation profiles in ovarian tumors: opportunities for
novel biomarkers. Int J Mol Sci 2018;19.
17. Choi JD, Lee JS. Interplay between epigenetics and genetics in cancer. Genomics Inform 2013;11:164-73.
18. Yang SD, Ahn SH, Kim JI. 3-Oxoacid CoA transferase 1 as a therapeutic target gene for cisplatin-resistant ovarian cancer. Oncol Lett
2018;15:2611-8.
19. Lund RJ, Huhtinen K, Salmi J, Rantala J, Nguyen EV, et al. DNA methylation and Transcriptome Changes Associated with Cisplatin
Resistance in Ovarian Cancer. Sci Rep 2017;7:1469.
20. Han X, Zhou Y, You Y, Lu J, Wang L, et al. TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian
cancer. Cell Biol Int 2017;41:405-14.
21. Fang F, Munck J, Tang J, Taverna P, Wang Y, et al. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer
chemosensitizer. Clin Cancer Res 2014;20:6504-16.
22. Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian
cancer identified by methylome and expression profiling. Oncogene 2012;31:4567-76.
23. Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug
resistance in ovarian cancer. Oncogene 1999;18:2335-41.
24. Matei D, Fang F, Shen C, Schilder J, Arnold A, et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 2012;72:2197-205.
25. Ha YN, Sung HY, Yang SD, Chae YJ, Ju W, et al Epigenetic modification of alpha-N-acetylgalactosaminidase enhances cisplatin
resistance in ovarian cancer. Korean J Physiol Pharmacol 2018;22:43-51.
26. Jin C, Yu W, Lou X, Zhou F, Han X, et al. UCHL1 is a putative tumor suppressor in ovarian cancer cells and contributes to cisplatin
resistance. J Cancer 2013;4:662-70.
27. Yu W, Jin C, Lou X, Han X, Li L, et al. Global analysis of DNA methylation by Methyl-Capture sequencing reveals epigenetic control
of cisplatin resistance in ovarian cancer cell. PLoS One 2011;6:e29450.
28. Olopade OI, Wei M. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 2003;3:417-20.
29. D'Andrea AD. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle 2003;2:290-2.
30. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, et al. Disruption of the Fanconi anemia-BRCA pathway in
cisplatin-sensitive ovarian tumors. Nat Med 2003;9:568-74.
31. Bonito NA, Borley J, Wilhelm-Benartzi CS, Ghaem-Maghami S, Brown R. Epigenetic regulation of the homeobox gene MSX1
associates with platinum-resistant disease in high-grade serous epithelial ovarian cancer. Clin Cancer Res 2016;22:3097-104.
32. Cui L, Liang B, Yang Y, Zhu M, Kwong J, et al. Inhibition of coiled coil domain containing protein 69 enhances platinum-induced
apoptosis in ovarian cancer cells. Oncotarget 2017;8:101634-48.
33. de Leon M, Cardenas H, Vieth E, Emerson R, Segar M, Liu Y, Nephew K, Matei D. Transmembrane protein 88 (TMEM88) promoter
hypomethylation is associated with platinum resistance in ovarian cancer. Gynecol Oncol 2016;142:539-47.
34. Lum E, Vigliotti M, Banerjee N, Cutter N, Wrzeszczynski KO, et al. Loss of DOK2 induces carboplatin resistance in ovarian cancer via
suppression of apoptosis. Gynecol Oncol 2013;130:369-76.